(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) dropped by a staggering 21.43% in 10 sessions from €0.14 to €0.11 at 05:08 EST on Wednesday, after three sequential sessions in a row of losses. BEL 20 is sliding 0.18% to €3,825.77, following the last session’s downward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.37.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.55%, a negative 0.57%, and a positive 5.71%.
BIOSENIC’s highest amplitude of average volatility was 4.55% (last week), 2.52% (last month), and 5.71% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for BIOSENIC is 552383 which is 50.63% below its average volume of 287648.
More news about BIOSENIC (BIOS.BR).
